{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:49:00Z","timestamp":1789422540730,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ecco-jccjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.crohns.2014.04.012","type":"journal-article","created":{"date-parts":[[2014,5,26]],"date-time":"2014-05-26T23:31:24Z","timestamp":1401147084000},"page":"1407-1416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease"],"prefix":"10.1093","volume":"8","author":[{"given":"Mamoru","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nael M.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Camez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Petersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopal","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2014.04.012_bb0005","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ibd.21506","article-title":"Development of the Crohn's disease digestive damage score, the L\u00e9mann score","volume":"17","author":"Pariente","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.04.012_bb0010","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/gut.34.12.1705","article-title":"Location of tumour necrosis factor \u03b1 by immunohistochemistry in chronic inflammatory bowel disease","volume":"34","author":"Murch","year":"1993","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2014.04.012_bb0015","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/gut.32.8.913","article-title":"Serum concentrations of tumour necrosis factor \u03b1 in childhood chronic inflammatory bowel disease","volume":"32","author":"Murch","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2014.04.012_bb0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumour necrosis factor alpha in stool as a marker of intestinal inflammation","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2014.04.012_bb0025","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2014.04.012_bb0030","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2014.04.012_bb0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.04.012_bb0040","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.04.012_bb0045","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1524-4733.2008.00335.x","article-title":"Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective","volume":"11","author":"Wu","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.crohns.2014.04.012_bb0050","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2014.04.012_bb0055","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.04.012_bb0060","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2014.04.012_bb0065","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.crohns.2014.04.012_bb0070","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/apt.12499","article-title":"Adalimumab maintains remission of Crohn's disease after up to 4years of treatment: data from CHARM and ADHERE","volume":"38","author":"Panaccione","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.04.012_bb0075","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","article-title":"Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease","volume":"6","author":"Watanabe","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2014.04.012_bb0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ibd.20352","article-title":"New global map of Crohn's disease: genetic, environmental, and socioeconomic correlations","volume":"14","author":"Economou","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.04.012_bb0085","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1365-2036.2010.04304.x","article-title":"Adalimumab sustains clinical remission and overall clinical benefit after 2years of therapy for Crohn's disease","volume":"31","author":"Panaccione","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.04.012_bb0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ibd.21328","article-title":"Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics","volume":"17","author":"Sandborn","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.04.012_bb0095","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1046\/j.1365-2036.2002.01323.x","article-title":"The quality of life in patients with Crohn's disease","volume":"16","author":"Cohen","year":"2002","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994614001573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994614001573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/8\/11\/1407\/1019822\/8-11-1407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T19:33:05Z","timestamp":1503430385000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2014.04.012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1873994614001573"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2014.04.012","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Crohn's and Colitis","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.crohns.2014.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}